Panel recommends Vioxx return to market in Canada

A medical advisory panel in Canada recommended Merck's painkiller Vioxx be allowed back on the market despite some cardiovascular risk, and also said Pfizer's Celebrex should remain on the market. The panel recommended Pfizer's other arthritis drug, Bextra, also a Cox-2 inhibitor, be kept off the market, and said ibuprofen pain relievers, currently sold OTC, should be subject to restrictions. Health Canada must now decide whether to accept the panel's recommendations.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA